International experts issue new MRI-based prostate cancer screening guidance - Radiology Business

International experts have just unveiled a landmark new consensus, the Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM) recommendations, poised to redefine prostate cancer screening globally. Published on June 11, 2026, in JAMA Oncology, this guidance, spearheaded by Imperial College London Dr. Nikhil Mayor, champions a streamlined, faster, and more cost-effective biparametric MRI (bpMRI) approach, aiming to improve early detection while reducing the harms associated with traditional screening. For years, prostate cancer screening, primarily via the Prostate-Specific Antigen (PSA) test, has wrestled with a thorny dilemma: its ability to reduce mortality often came at the cost of overdiagnosis and unnecessary biopsies. Magnetic Resonance Imaging (MRI) emerged as a more precise tool, but a lack of standardized protocols hindered its widespread adoption. The PRISM recommendations directly address this gap, building on compelling evidence, including the recent PRIME trial which demonstrated bpMRI non-inferiority to the more complex multiparametric MRI (mpMRI) for detecting clinically significant prostate cancer, signaling a pivotal shift towards more intelligent, patient-centric screening paradigms. The new guidance calls for MRI screening in men aged 50-70 (or 45 for Black men), typically following an initial PSA test, and crucially, mandates these scans be performed in accredited centers by trained radiologists using a 'stage-gated' reading approach. This move is expected to catalyze a broader, more consistent integration of advanced imaging into prostate cancer pathways, informing ongoing large-scale initiatives like the TRANSFORM trial and promising a future where early detection is both effective and less burdensome for millions of men worldwide.